Celebrating the launch of landmark clinical trials IAVI G004, IAVI C114, and BRILLIANT 011.
IAVI feature article for HIV Vaccine Awareness Day 2026
May 18 marks HIV Vaccine Awareness Day (HVAD) in recognition of the tireless search for a tool that could help end one of the most complex public health threats of our time. In 2024 alone, approximately 1.3 million people acquired HIV and 630,000 people lost their lives to AIDS-related causes. These numbers are estimated to have increased in the past year due to global HIV funding cuts, which have resulted in unprecedented disruptions to lifesaving treatment and care, education and community health programs, innovative research and clinical trials, and more.
The situation on the ground illustrates exactly why we still need an HIV vaccine. Alongside new long-acting prevention options such as lenacapavir, a vaccine can offer more durable, widespread immunity that alleviates the strain on high-burden and resource-constrained settings. However, years of scientific progress are currently under threat from the rapid loss of funding and political commitment.
In this challenging environment, the difficult task of testing new HIV vaccine candidates must persist. For HVAD 2026, IAVI spotlights the clinical trials that have launched in the past year despite considerable obstacles. These programs are led by IAVI and partners across the field, in close collaboration with community members.
Read the full article here.
Source : IAVI
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.